Evidence-based medicine and clinical trials

被引：7

作者：

Coyle, Patricia K. ^{[1
]}

机构：

[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA

来源：

NEUROLOGY | 2007年 / 68卷

关键词：

D O I：

10.1212/01.wnl.0000277702.74115.9b

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Optimal treatment of disease processes requires an objective assessment of clinical trial data in addition to careful patient monitoring. For multiple sclerosis ( MS), the available treatments have been sufficiently evaluated in relapsing-remitting MS (RRMS), and physicians should treat MS patients to the standard of care recommended by the National Multiple Sclerosis Society and/or the American Academy of Neurology. In some cases, recommendations must be made in the absence of definitive clinical trial data. Physicians should understand the limitations of recommendations of this type and still apply a combination of careful clinical evaluation, assessment of patient and disease factors, and an objective evaluation of whatever clinical trial data are available when treatment decisions are made.

引用

页码：S3 / S7

页数：5

共 18 条

[1] Every-other-clay interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb [J].

Barbero, P ;

Bergui, M ;

Versino, E ;

Ricci, A ;

Zhong, JJ ;

Ferrero, B ;

Clerico, M ;

Pipieri, A ;

Verdun, E ;

Giordano, L ;

Durelli, L .

MULTIPLE SCLEROSIS JOURNAL, 2006, 12 (01) :72-76

[2] Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].

Comi, G ;

Filippi, M ;

Barkhof, F ;

Durelli, L ;

Edan, G ;

Fernández, O ;

Hartung, HP ;

Seeldrayers, P ;

Sorensen, PS ;

Rovaris, M ;

Martinelli, V ;

Hommes, OR .

LANCET, 2001, 357 (9268) :1576-1582

[3] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[4] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[5] The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology [J].

Goodin, DS ;

Arnason, BG ;

Coyle, PK ;

Frohman, EM ;

Paty, DW .

NEUROLOGY, 2003, 61 (10) :1332-1338

[6] Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [J].

Goodin, DS ;

Frohman, EM ;

Garmany, GP ;

Halper, J ;

Likosky, WH ;

Lublin, FD ;

Silberberg, DH ;

Stuart, WH ;

van den Noort, S .

NEUROLOGY, 2002, 58 (02) :169-178

[7] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. [J].

Jacobs, LD ;

Beck, RW ;

Simon, JH ;

Kinkel, RP ;

Brownscheidle, CM ;

Murray, TJ ;

Simonian, NA ;

Slasor, PJ ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :898-904

[8] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[9] COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

JOHNSON, KP ;

BROOKS, BR ;

COHEN, JA ;

FORD, CC ;

GOLDSTEIN, J ;

LISAK, RP ;

MYERS, LW ;

PANITCH, HS ;

ROSE, JW ;

SCHIFFER, RB ;

VOLLMER, T ;

WEINER, LP ;

WOLINSKY, JS ;

BIRD, SJ ;

CONSTANTINESCU, C ;

KOLSON, DL ;

GONZALEZSCARANO, F ;

BRENNAN, D ;

PFOHL, D ;

MANDLER, RN ;

ROSENBERG, GA ;

JEFFREY, C ;

BARGER, GR ;

GANDHI, B ;

MOORE, PM ;

ROGERS, LR ;

LISAK, D ;

SMITH, L ;

ELLISON, GW ;

BAUMHEFNER, RW ;

CRAIG, SL ;

JALBUT, SS ;

KATZ, E ;

CONWAY, KL ;

BURNS, JB ;

SHIBA, C ;

GIANG, DW ;

PETRIE, MD ;

GUARNACCIA, JB ;

ANDERSON, S ;

MCKEON, A ;

MCCARTHY, M ;

THOMAS, AB ;

VRIESENDORP, FJ ;

AUSTIN, SG ;

LINDSEY, JW ;

DIMACHKIE, M ;

CERRETA, E ;

KACHUCK, N ;

MCCARTHY, KA .

NEUROLOGY, 1995, 45 (07) :1268-1276

[10] Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis [J].

Kappos, L ;

Polman, C ;

Pozzilli, C ;

Thompson, A ;

Dahlke, F ;

Knight, R ;

Hern, J ;

Coleman, R ;

Gerrie, L ;

Cooper, G ;

Moore, J ;

Boringa, J ;

van Oosten, B ;

Ronner, H ;

Schrijver, H ;

Truyen, L ;

Montalbán, J ;

Río, J ;

Tintoré, M ;

Jacas, C ;

Marzo, E ;

Lechner-Scott, J ;

Huber, S ;

Lienert, C ;

Brunnschweiler, H ;

Hawkins, S ;

Droogan, A ;

McDonnell, G ;

Duddy, M ;

McKinstry, S ;

Altenkirch, H ;

Baum, K ;

Einhäupl, K ;

Marx, P ;

Poewe, W ;

Walter, G ;

Akman, H ;

Brockmeier, B ;

Scherer, P ;

Zschenderlein, R ;

Schmierer, K ;

Gelderblom, H ;

Hartmann, A ;

Stapf, C ;

Lüschow, A ;

Mackert, B ;

Schumacher, H ;

Masuhr, F ;

Hempel, T ;

Zimmermann, R .

LANCET, 1998, 352 (9139) :1491-1497

← 1 2 →